. 2020 Mar 30;55(1):10–16. doi: 10.5045/br.2020.55.1.10
© 2020 Korean Society of Hematology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Fig. 3. CAR T-cell therapy for AML.
